Her2-CD3 bispecific antibody specifically activated in the tumor microenvironment

A mutant CD3 antibody with targeted mutations and a masking moiety, activated in the tumor microenvironment, addresses side effects and enhances anti-tumor activity, providing a safer and more effective treatment.

JP2025527664APending Publication Date: 2025-08-22YING MAI DE MEDICAL TECH (GUANGDONG) CO LTD
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2025511476
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-22
Filing Date
2023-08-16
Publication Date
2025-08-22

AI Technical Summary

Technical Problem

Multispecific antibodies face challenges with side effects such as cytokine storms and neurotoxicity, as well as manufacturing process issues, necessitating the development of antibodies with high safety, strong specificity, and high anti-tumor activity.

Method used

A mutant CD3 antibody with specific mutations in the complementarity determining regions, linked to a masking moiety via a thermolytic peptide, is activated in the tumor microenvironment to enhance anti-tumor activity while minimizing side effects.

Benefits of technology

The mutant CD3 antibody, when activated in the tumor microenvironment, stimulates an effective anti-tumor immune response, reducing cytokine storms and increasing dosage efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025527664000021
    Figure 2025527664000021
  • Figure 2025527664000022
    Figure 2025527664000022
  • Figure 2025527664000023
    Figure 2025527664000023
Patent Text Reader

Abstract

The present invention relates to a Her2-CD3 bispecific antibody that is specifically activated in the tumor microenvironment. Specifically, the bispecific antibody is highly expressed in the tumor environment and chemically linked to a recognizable and cleavable substrate and masking moiety. The bispecific antibody of the present invention inhibits antibody activity in normal tissues and activates antibody activity in the tumor environment. Furthermore, the bispecific antibody of the present invention has significantly reduced toxic side effects.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Tri-specific antigen binding construct, and construction method and application thereof

    CN112794916A

  • ANTI-CD3 humanized antibody

    CN113461821A

  • Engineered antibodies that bind irreversibly

    JP2003516121A

  • CD3-binding molecules capable of binding to human and non-human CD3.

    JP2014517844A

  • CD3 binding molecules capable of binding to human and non human CD3

    JP2017206505A